This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greco, F. A. Articles by Hainsworth, J. D. Search for Related Content PubMed PubMed Citation Articles by Greco, F. A. Articles by Hainsworth, J. D.

Carcinoma of Unknown Primary Site: Sequential Treatment with Paclitaxel/Carboplatin/Etoposide and Gemcitabine/Irinotecan: A Minnie Pearl Cancer Research Network Phase II Trial

^a The Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville, Tennessee, USA; ^b South Texas Oncology and Hematology, PA, San Antonio, Texas, USA; ^c Northwest Georgia Oncology Centers, PC, Marietta, Georgia, USA

Correspondence: F. Anthony Greco, M.D., Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 110, Nashville, Tennessee 37203, USA. Telephone: 615-986-4300; Fax: 615-986-0029; e-mail: fgreco{at}tnonc.com

Purpose. To evaluate the efficacy and toxicity of the sequential administration of paclitaxel (Taxol^®; Bristol-Myers Squibb; Princeton, NJ), carboplatin (Paraplatin^®; Bristol-Myers Squibb), and oral etoposide (VePesid^®; Bristol-Myers Squibb) followed by gemcitabine (Gemzar^®; Eli Lilly; Indianapolis, IN) and irinotecan (Campostar^®; Pfizer Pharmaceuticals; New York, NY) in the first-line treatment of patients with carcinoma of unknown primary site.

Patients and Methods. One hundred thirty-two patients were treated with sequential combination chemotherapy for a maximum of six cycles. All patients had relatively poor prognostic features. Fifty-nine patients had well-differentiated adenocarcinoma, 73 patients had poorly differentiated carcinoma, and 121 patients had performance status scores of 0 or 1.

Results. Thirty-three (30%) of 111 assessable patients (95% confidence interval 27%–33%) had objective responses to treatment (26 partial responses, seven complete responses). The combination of gemcitabine and irinotecan was associated with significantly less toxicity than the triple-drug regimen and improved the responses in several patients (10%). The response rates were similar in the two major histologic tumor types, but were lower for patients with liver-dominant tumors (13%) and higher for patients with lymph-node-dominant tumors (50%). The median progression-free survival time, median survival time, and actuarial survival rates at 1 and 2 years were 5.7 months, 9.1 months, 35%, and 16%, respectively.

Conclusions. Sequential combination chemotherapy with paclitaxel/carboplatin/oral etoposide and gemcitabine/irinotecan is an active treatment for patients with carcinoma of unknown primary site, but overall toxicities are greater than those seen with other combinations of new drugs and survival appears similar to that observed in 264 other patients treated in our four previous phase II trials. A better understanding of the biology of these heterogeneous tumors will likely lead to improved therapy for these patients.

Key Words. Carcinoma • Unknown • Chemotherapy • Sequential • Metastasis • Survival

This article has been cited by other articles:

				G. R. Varadhachary, D. Talantov, M. N. Raber, C. Meng, K. R. Hess, T. Jatkoe, R. Lenzi, D. R. Spigel, Y. Wang, F. A. Greco, et al. Molecular Profiling of Carcinoma of Unknown Primary and Correlation With Clinical Evaluation J. Clin. Oncol., September 20, 2008; 26(27): 4442 - 4448. [Abstract] [Full Text] [PDF]

				D. Talantov, J. Baden, T. Jatkoe, K. Hahn, J. Yu, Y. Rajpurohit, Y. Jiang, C. Choi, J. S. Ross, D. Atkins, et al. A Quantitative Reverse Transcriptase-Polymerase Chain Reaction Assay to Identify Metastatic Carcinoma Tissue of Origin J. Mol. Diagn., July 1, 2006; 8(3): 320 - 329. [Abstract] [Full Text] [PDF]